Immunome develops targeted cancer therapies, with a focus on antibody drug conjugates and an investigational treatment for desmoid tumors. It last closed at $15.69 on Nov 20, down 5.54% on the day. The next earnings report for IMNM is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, IMNM reported EPS of -$0.76 on revenue of $0. Over its last 8 reports the stock moved an average of 3.2% the session after earnings. Over the last 12 months IMNM insiders bought $2.3M of stock on the open market and sold $27.5M, according to SEC Form 4 filings.
AI Auto Pilots
Is IMNM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IMNM.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on IMNMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
IMNM · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 17% below its 20 day and 26% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the 52 week low at $15.55, and the nearest resistance the Pivot at $15.99.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.9%/day
Key levels
$30.0652 week high+91.6%
$22.50100 day average+43.4%
$21.99200 day average+40.2%
$19.7450 day average+25.8%
$18.44Swing high (Oct 21)+17.5%
$18.3220 day average+16.8%
$16.43Pivot R1+4.7%
$15.99Pivot+1.9%
$15.69Last close
$15.5552 week low−0.9%
$15.25Pivot S1−2.8%
Indicators
RSI (14)
31.96
Weak, oversold below 30
Neutral
MACD
-0.82
Below its signal line
Bearish
Stochastic
2.2
Near the bottom of its range
Oversold
ADX (14)
20.1
Weak trend
Williams %R
-98.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-220.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−16.1%
Change over 10 sessions
Bearish
ATR (14)
$1.23
Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 17.9%/day
Key levels
$30.0652 week high+91.6%
$22.50100 day average+43.4%
$21.99200 day average+40.2%
$19.7450 day average+25.8%
$18.44Swing high (Oct 21)+17.5%
$18.3220 day average+16.8%
$16.43Pivot R1+4.7%
$15.99Pivot+1.9%
$15.69Last close
$15.5552 week low−0.9%
$15.25Pivot S1−2.8%
Indicators
RSI (14)
34.79
Weak, oversold below 30
Neutral
MACD
-1.21
Below its signal line
Bearish
Stochastic
11.7
Near the bottom of its range
Oversold
ADX (14)
20.9
Weak trend
Williams %R
-99.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-126.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−36.4%
Change over 10 sessions
Bearish
ATR (14)
$2.80
Typical daily range, 17.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for IMNM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IMNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow IMNM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for IMNMHow many large options trades hit IMNM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in IMNM in the last 90 days.
From SEC Form 4 filings by IMNM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMNM is in one of them and how their past IMNM trades turned out.
Immunome is a biotechnology company based in Bothell, Washington, that develops targeted cancer treatments. Its main focus is antibody drug conjugates, a type of therapy that carries cancer fighting drugs to tumor cells, along with other oncology therapies. Its lead candidate, varegacestat, is an investigational oral treatment for desmoid tumors, a rare connective tissue tumor. The company aims to serve cancer patients and the doctors who treat them.